Cosmos Health Inc. announces a $300 million agreement to launch an Ethereum digital asset treasury strategy, enhancing shareholder value.
Quiver AI Summary
Cosmos Health Inc. has announced a securities purchase agreement with a U.S.-based institutional investor, which allows for the issuance of up to $300 million in senior secured convertible promissory notes. This agreement aims to facilitate the company's Ethereum digital asset treasury reserve strategy, intending to accumulate ETH to increase long-term shareholder value. The ETH assets will be stored and staked through BitGo Trust Company, and the initiative aligns with Cosmos Health's ongoing digital transformation, potentially enhancing areas like supply chain traceability and global consumer engagement. CEO Greg Siokas emphasized that this financing is not a temporary shift but part of a long-term commitment to innovation, aiming to drive growth in product development and other strategic initiatives. The company plans to allocate a significant portion of the funds raised toward its digital asset treasury, with the rest supporting working capital and various growth efforts.
Potential Positives
- Cosmos Health secured a significant financing arrangement of up to $300 million through senior secured convertible promissory notes, enhancing its capital base for strategic initiatives.
- The company's planned entry into the Ethereum (ETH) digital asset treasury reserve strategy could potentially increase long-term shareholder value by accumulating ETH assets.
- Partnership with BitGo Trust Company for asset custody and staking showcases a commitment to utilizing institutional infrastructure for managing digital assets.
- This financing will support key growth initiatives including accelerated product development, advanced R&D innovation, and the planned entry into U.S. manufacturing.
Potential Negatives
- The company is planning to raise a significant amount of capital ($300 million) through the issuance of convertible promissory notes, which may indicate a lack of sufficient cash flow from existing operations.
- Investment in a digital asset treasury reserve strategy could be seen as risky or speculative, particularly in a volatile market, which may raise concerns among investors about the company's financial stability.
- There are conditions attached to the securities purchase agreement, which may introduce uncertainties regarding the execution and timing of these financing efforts.
FAQ
What is the recent announcement by Cosmos Health about?
Cosmos Health announced a securities purchase agreement for up to $300 million in convertible promissory notes to launch an Ethereum treasury reserve strategy.
How will Cosmos Health utilize the funds from the securities purchase agreement?
The funds will primarily support the digital asset treasury reserve and various growth initiatives, including product development and commercial initiatives.
What is the significance of Cosmos Health's Ethereum strategy?
The Ethereum strategy aims to enhance long-term shareholder value by accumulating ETH and exploring its potential in various business applications.
Who is involved in providing infrastructure for Cosmos Health's treasury initiative?
BitGo Trust Company, Inc. is providing institutional infrastructure for the custody and staking of Cosmos Health's Ethereum assets.
What are the future plans for Cosmos Health regarding digital assets?
Cosmos Health plans to explore additional yield-generating strategies related to its ETH holdings and investigate various blockchain use cases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$COSM Insider Trading Activity
$COSM insiders have traded $COSM stock on the open market 13 times in the past 6 months. Of those trades, 13 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $COSM stock by insiders over the last 6 months:
- GRIGORIOS SIOKAS (Chief Executive Officer) has made 13 purchases buying 2,616,164 shares for an estimated $1,095,977 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$COSM Hedge Fund Activity
We have seen 8 institutional investors add shares of $COSM stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC added 1,168,884 shares (+156.1%) to their portfolio in Q1 2025, for an estimated $509,633
- SLT HOLDINGS LLC removed 42,500 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $17,850
- FOUNDATIONS INVESTMENT ADVISORS, LLC added 42,500 shares (+inf%) to their portfolio in Q1 2025, for an estimated $18,530
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 42,272 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $18,430
- XTX TOPCO LTD removed 32,617 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $14,221
- VIRTU FINANCIAL LLC removed 29,787 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $12,987
- TWO SIGMA SECURITIES, LLC removed 23,544 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $10,265
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
CHICAGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, announced today that it has entered into a securities purchase agreement with a U.S.-based institutional investor for the issuance of up to $300 million in senior secured convertible promissory notes (the “Facility”), subject to the satisfaction or waiver of certain conditions, to support the launch of its Ethereum (ETH) digital asset treasury reserve strategy.
Key Highlights:
-
Strategic accumulation of ETH to enhance long-term shareholder value through increasing ETH-per-share
-
ETH assets will be custodied and staked through institutional infrastructure provided by BitGo Trust Company, Inc. (“BitGo”)
-
Treasury initiative complements Cosmos Health’s ongoing digital transformation and e-commerce efforts, with potential to explore blockchain use cases in supply chain traceability, wellness incentive programs, and global consumer engagement
-
The Company plans to explore additional yield-generating strategies to optimize cash flow and utility from ETH holdings
Greg Siokas, CEO of Cosmos Health, stated: “This financing marks a strategic milestone for Cosmos Health, offering shareholders direct exposure to ETH, currently one of the most widely adopted digital assets in the world. It also provides access to growth capital to support a range of strategic initiatives, including accelerated product development, advanced R&D innovation, enhanced commercial initiatives, and our planned entry into U.S. manufacturing.”
“Our entry into the digital asset space is not a short-term pivot, but part of a broader commitment to innovation,” Greg Siokas continued. “We are confident that the size and flexibility of this facility should position us to deliver long-term, sustainable value for our shareholders.”
Under the terms of the Facility, Cosmos Health is required to allocate at least 72.5% of the net proceeds from each tranche closing toward building its digital asset treasury reserve, with the remainder to be used for working capital and various growth initiatives.
Curvature Securities, LLC acted as the sole placement agent in connection with the Facility.
The foregoing description is a summary only and does not purport to be complete. For further information, please refer to Cosmos Health’s Current Report on Form 8-K, which will be available on the Securities and Exchange Commission’s website at www.sec.gov .
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com , www.skypremiumlife.com , www.cana.gr , www.zipdoctor.co , www.cloudscreen.gr , as well as LinkedIn and X .
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. Such forward-looking statements include, but are not limited to, the Company’s expectation that accumulation of ETH will enhance long-term shareholder value through increasing ETH-per-share, the Company’s plans to explore additional yield-generating strategies to optimize cash flow and utility from ETH holdings, that the Facility will provide access to growth capital to support a range of strategic initiatives, including accelerated product development, advanced R&D innovation, enhanced commercial initiatives, and the Company’s planned entry into U.S. manufacturing and the anticipated use of proceeds. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (
www.sec.gov
). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
BDG Communications
[email protected]